News|Articles|November 19, 2026

FDA Clears CCTA-Based AI Software for Facilitating Management of Coronary Artery Disease

Author(s)Jeff Hall

Utilizing data from CCTA scans, the Syngo.CT Coronary Cockpit reportedly provides AI-automated analysis of coronary plaque.

The Food and Drug Administration (FDA) has granted 510(k) clearance for Syngo.CT Coronary Cockpit, an AI-powered software that may enhance coronary plaque assessment on coronary computed tomography angiography (CCTA) scans and provide adjunctive support for planning of percutaneous coronary intervention (PCI) procedures.

Residing within the Syngo.via imaging software platform,Syngo.CT Coronary Cockpit provides automated characterization of plaque quantity and morphology within individual lesions or the coronary tree, according to Siemens Healthineers, the manufacturer of the software.

Through a combination of AI-based segmentation and labeling, Siemens Healthineers said the Syngo.CT Coronary Cockpit software bolsters risk stratification and clinician decision-making for treating patients with coronary artery disease (CAD).

“With Syngo.CT Coronary Cockpit, clinicians can obtain advanced insights from a patient’s CT scan to support a more comprehensive assessment of cardiac health and better inform treatment decisions, ultimately helping people with coronary artery disease live longer, healthier lives,” said Olivia Egan, the head of computed tomography at Siemens Healthineers North America.


Related to this article